

ACL Laboratories COVID-19 and Influenza Activity Report

Updated: Aug 15, 2021




RESPIRATORY PATHOGEN PANEL 2021

Positivity Rate (%)


MONTH	FLU A	FLU H1 (H1-A)	2009 H1N1 (H1-B)	H3	FLU B	RSV A	RSV B	RSV A/B	PARA 1	PARA 2	PARA 3	PARA 4	COR 229E	COR NL63	COR OC43	COR HKU1	META	E/R	ADENO	BOCA	LEG	CHL	MYCO
JAN	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.1	0.7	0.3	0.0	0.0	0.0
FEB	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.2	6.1	0.2	0.3	0.0	0.0	0.0
MAR	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.3	0.4	0.1	0.1	0.3	0.1	1.4	0.9	0.1	0.4	12.2	1.2	0.3	0.0	0.1	0.1
APR	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.2	0.5	0.0	0.0	2.5	2.9	0.0	0.8	15.3	1.4	1.2	0.0	0.0	0.0
MAY	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.7	3.9	0.0	0.2	1.4	3.9	0.0	0.0	14.4	1.7	1.4	2.7	0.0	0.1
JUN	0.0	0.0	0.0	0.0	0.0	0.1	1.8	1.9	0.0	0.3	9.6	0.0	0.3	0.4	2.4	0.0	0.1	15.8	1.1	1.8	0.0	0.0	0.1
JUL	0.0	0.0	0.0	0.0	0.0	1.0	7.2	8.2	0.1	0.5	12.9	0.0	0.1	0.4	1.4	0.0	0.5	18.9	1.6	4.4	4.3	0.0	0.0
AUG	0.0	0.0	0.0	0.0	0.0	1.0	11.9	12.9	0.0	0.2	8.0	0.0	0.0	0.3	0.8	0.0	0.3	13.0	1.1	3.7	0.0	0.0	0.0
SEP																							
OCT																							
NOV																							
DEC																							

Increased prevalence of viruses: **RSV (type B), Parainfluenza 3 and Rhinovirus.**


Parainfluenza 3 POSITIVITY RATE 2021 (%)



RPP RSV POSITIVITY RATE 2021 (%)




ACL RSVAG and PCR - Pos rate (%) - Aug 15, 2021




ACL RSV PCR by Cepheid assay was started on Aug 8th 2021

CDC Data RSV pos rate for Region 5 Chicago - (PCR - 16%, Antigen - 26%)

Total PCR Tests





Total Antigen Tests




SARS-COV-2					Influenza - no activity				RSV (Antigen+PCR)			
Week	IL % SCVPCR	WI % SCVPCR	IL % COVAG	WI % COVAG	IL % FLUPCR	WI % FLUPCR	IL % FLUAG	WI % FLUAG	IL % RSVAG	WI % RSVAG	IL % RSVPCR	WI % RSVPCR
Aug 15	6.6	6.8	9.8	18.0	0	0	0	0	25.9	23.5	27.0	16.7
Aug 8	6.8	7.4	9.8	15.8	0	0	0	0	14.6	22.7	25.7	16.9
Aug 1	3.8	6.9	10.5	17.6	0	0	0	0	32.1	22.0	0.0	0.0
Jul 25	2.7	4.1	8.0	11.8	0	0	0	0	15.5	16.7	0.0	0.0
Jul 18	1.8	2.6	1.4	7.2	0	0	0	0	15.6	21.6	0.0	0.0
Jul 11	1.6	1.6	1.0	5.0	0	0	0	0	16.7	17.4	0.0	0.0
Jul 4	1.6	1.4	0.0	3.0	0	0	0	0	15.5	15.5	0.0	0.0
Jun 27	1.7	1.5	1.5	2.8	0	0	0	0	11.1	8.3	0.0	0.0
Jun 20	1.5	1.2	1.5	1.1	0	0	0	0	7.1	3.2	0.0	0.0
Jun 13	1.6	1.2	1.4	2.7	0	0	0	0	8.6	3.7	0.0	0.0
Jun 06	2.5	1.6	2.6	2.7	0	0	0	0	5.0	0.0	0.0	0.0

ACL RSV tests results are consistent with “atypical” summer RSV outbreak


ACL COVAG and SCVPCR - Pos rate (%) - Aug 15, 2021



Aug 11, 2021 - daily COVID-19 cases in US - CDC




Aug 7, 2021 – SARS-CoV-2 circulating in the US (~97.4% % Delta variants)



US vaccination status CDC | Data as of: Aug 12, 2021



353,859,894 Vaccines Administered	
196,505,543 People who received at least one dose	167,354,729 People who are fully vaccinated*
59.2% Percentage of the US population that has received at least one dose	50.4% Percentage of the US population that has been fully vaccinated*

Influenza Positive Tests Reported to CDC by U.S. Clinical Laboratories, National Summary, September 27, 2020 – August 7, 2021




2020-21 Influenza Season Week 31 ending Aug 07, 2021


ILI Activity Level



CSF targets positivity rate is 6.7% (VZV and HHV6)



The most prevalent GI bacterial target is (Cryptosporidium 1.8%)



The most prevalent GI viral target is – (Norovirus II – 0.4%)

